Could Bayer’s NUBEQA gain a quality-of-life edge after ARACOG cognitive data?

Find out how Bayer’s NUBEQA cognitive data from ARACOG could reshape prostate cancer treatment choices after ASCO 2026.

Find out how Bayer’s NUBEQA cognitive data from ARACOG could reshape prostate cancer treatment choices after ASCO 2026.

Talzenna plus Xtandi improved rPFS in HRR-mutated metastatic prostate cancer. Find out what TALAPRO-3 could change next.